For GSK, Lots Of Drugs In R&D, But Many Are Long-Term
Executive Summary
Management highlighted pipeline drugs in respiratory disease, HIV, immuno-oncology and vaccines, but a lot of the drugs in development are early- to mid-stage where the success rate remains uncertain. The meeting isn’t likely to change investor sentiment in the near-term.
You may also be interested in...
GSK Kicks Off Two Large Outcomes Trials In A Competitive CKD Category
The company initiated a Phase III development program for the oral HIF-PH inhibitor daprodustat as a treatment for anemia associated with chronic kidney disease. Two trials will enroll 7,500 patients.
Swapping Assets Now Down To Execution For GSK And Novartis
Being successful with products originally marketed by the other will be key to the future growth and bragging rights for two leading European Big Pharmas, GlaxoSmithKline and Novartis.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.